Drug Interactions between boceprevir and Razadyne ER
This report displays the potential drug interactions for the following 2 drugs:
- boceprevir
- Razadyne ER (galantamine)
Interactions between your drugs
galantamine boceprevir
Applies to: Razadyne ER (galantamine) and boceprevir
MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of galantamine, which is partially metabolized by the isoenzyme. In multiple dose pharmacokinetic studies, a potent CYP450 3A4 inhibitor such as ketoconazole has been shown to increase galantamine systemic exposure (AUC) by 30%. Erythromycin and cimetidine, which are less potent inhibitors, have been shown to increase galantamine AUC by 10% and 16%, respectively.
MANAGEMENT: Pharmacologic response to galantamine should be monitored more closely whenever a potent CYP450 3A4 inhibitor (e.g., clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors) is added to or withdrawn from therapy, and the galantamine dosage adjusted as necessary. Patients should be advised to notify their physician if they experience excessive cholinergic symptoms such as severe nausea, vomiting, GI cramping, salivation, lacrimation, sweating, dizziness, or syncope.
References
- "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals PROD (2001):
Drug and food interactions
boceprevir food
Applies to: boceprevir
ADJUST DOSING INTERVAL: Food significantly enhances the oral bioavailability of boceprevir. When given at 800 mg three times daily with food, boceprevir exposure increased by up to 65% relative to administration in the fasting state. The bioavailability of boceprevir was similar regardless of meal type (e.g., high-fat versus low-fat) or whether taken 5 minutes prior to eating, during a meal, or immediately following completion of the meal. Therefore, boceprevir may be taken without regard to either meal type or timing of the meal.
MANAGEMENT: To ensure maximal oral absorption, boceprevir should be administered with a meal or light snack.
References
- "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation (2011):
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.